Kimberly-Clark will pay $21.01 a share for Kenvue in a cash-and-stock deal valued at $48.7 billion, the consumer health brands said in a statement.Learn more: https://t.co/jhnuzyVTPR📸: Valerie Macon/AFP via Getty Images https://t.co/2U6HPcp6H9 ...

Exclusive: Kimberly-Clark not only saved its embattled rival, Kenvue, with a $40 billion takeover deal. It also saved activist hedge funds targeting the Tylenol-maker who had been staring down massive losses. https://t.co/vOUHIYFOKB ...

D.E. Shaw, one of the Tylenol-maker's largest shareholders, stood to lose over $200 million but is now expected to break even on its bet. ...

Group 1: Market Overview - US stock indices opened higher, with Dow Jones up 0.06%, S&P 500 up 0.49%, and Nasdaq up 0.97% [1] - Amazon surged over 4% after signing a $38 billion agreement with OpenAI to expand computing power using Nvidia chips [1] - Nvidia rose over 2% as Microsoft received export licenses to ship Nvidia's A100, H100, and H200 GPUs to the UAE [1] - Google opened slightly higher by 0.1%, planning to issue $15 billion in dollar bonds [1] Group 2: Company News - Microsoft plans to invest nearly $8 billion in the UAE by 2029, with over $5.5 billion allocated for AI and cloud infrastructure expansion [2] - IREN announced a $9.7 billion GPU cloud service contract with Microsoft, including a 20% upfront payment, and a separate $5.8 billion agreement with Dell for GPU and related equipment [3] - BP announced the sale of non-controlling interests in US onshore assets for $1.5 billion, reducing its stake in certain areas [4] - Kimberly plans to acquire Kenvue for approximately $48.7 billion through a cash and stock transaction [5] - BASF will integrate its Asian PolyTHF business into its China facility and close its Ulsan plant in South Korea by 2026 [6]

Kimberly-Clark Buys Embattled Tylenol Maker Kenvue In $48 Billion Dealhttps://t.co/fnF2xEKaWu https://t.co/Ja1OQJBs7p ...

Core Viewpoint - Kimberly-Clark is acquiring Kenvue, the maker of Tylenol, in a deal valued at over $48 billion, expected to close in the second half of 2026, pending regulatory and shareholder approvals [1][2]. Group 1: Deal Overview - The merger will create a combined company with significant consumer goods brands, including Kenvue's Tylenol, Band-Aid, and Benadryl, alongside Kimberly-Clark's Kleenex, Cottonelle, and Huggies [1]. - The new entity is projected to generate an annual revenue of $32 billion [3]. - Current Kimberly-Clark shareholders will own approximately 54% of the combined company, while Kenvue shareholders will hold about 46% [3]. Group 2: Financial Terms - Under the terms of the transaction, Kenvue shareholders will receive $3.50 per share in cash and 0.14625 Kimberly-Clark shares for each Kenvue share held at closing, totaling $21.01 per share based on Kimberly-Clark's closing price on October 31 [4]. Group 3: Market Reaction - Following the announcement, Kimberly-Clark's stock fell by over 12%, while Kenvue's stock rose by more than 15% in morning trading on November 3 [5]. - Despite the gains on November 3, Kenvue's stock is down approximately 22% year-to-date, and Kimberly-Clark's stock has decreased by about 20% in 2025 [5]. Group 4: Contextual Background - The acquisition follows a tumultuous period for Kenvue, which included the ousting of its CEO in July and controversy surrounding Tylenol's alleged link to autism, as promoted by former President Trump [2][6]. - Medical professionals have largely disputed the claims linking Tylenol to autism, asserting that there is no definitive evidence supporting such a connection [6].

Kimberly Clark reaching a deal to acquire Ken View for more than $40 billion. David Faber joins us with the details. Although I guess David, we've been watching the way Kimberly Clark shares have been trading in reaction to this news.There is an equity component of this uh proposed transaction. So maybe that brings it below the $40 billion uh number, but what can you tell us about some of the ins and outs here. >> Yeah, sure, Mike.You know, it's something I've been tracking. we've been discussing for quite ...

Core Insights - Kenvue missed Wall Street estimates for third-quarter sales, reporting net sales of $3.76 billion, below the expected $3.84 billion [4] - The company announced its acquisition by Kimberly-Clark for approximately $48.7 billion, leading to a 20% increase in its shares during premarket trading [1] - Kenvue's self-care segment, which includes brands like Tylenol, experienced a 3.8% decline in sales to $1.56 billion [3] Financial Performance - Kenvue's third-quarter net sales decreased by 3.5% compared to the previous year [4] - The adjusted profit was reported at 28 cents per share, slightly above the estimate of 27 cents [4] - The company reiterated its 2025 adjusted profit outlook of between $1.00 and $1.05 per share, with expectations of low-single-digit declines in net sales for that year [5] Management Changes - Kenvue appointed Kirk Perry as its permanent CEO, along with two other executives from Procter & Gamble and Mondelēz International [4] - The leadership change follows increased investor pressure due to weaknesses in Kenvue's core businesses, particularly in skin health and beauty [3]

Group 1: Market Overview - U.S. stock futures showed mixed results, with Nasdaq futures gaining over 100 points [1] Group 2: Kimberly-Clark Corporation - Kimberly-Clark Corporation announced the acquisition of Kenvue in a cash and stock transaction valued at approximately $48.7 billion [1] - Following the announcement, Kimberly-Clark shares fell sharply by 13.6% to $103.50 in pre-market trading [1] Group 3: Other Notable Stock Movements - uniQure N.V. shares dropped 65.3% to $23.40 after receiving FDA feedback regarding its investigational gene therapy AMT-130 [3] - ClearPoint Neuro, Inc. saw a decline of 40.5% to $13.77 in pre-market trading [3] - ALPS Group Inc fell 40.2% to $1.53 following the announcement of a public offering [3] - Biohaven Ltd. shares decreased by 27.4% to $12.48 [3] - Alvotech experienced a 24.1% drop to $5.80 after receiving an FDA Complete Response Letter for its AVT05 biosimilar application [3] - Replimune Group, Inc. dipped 16.7% to $8.10, despite an upgrade from BMO Capital [3] - Praxis Precision Medicines, Inc. declined 9.1% to $180.70 [3] - Vertex, Inc. fell 6.1% to $21.50 after lowering its FY2025 sales guidance [3]

Group 1 - U.S. stock futures showed mixed results, with Nasdaq futures gaining over 100 points [1] - Kimberly-Clark Corporation announced the acquisition of Kenvue for approximately $48.7 billion, leading to a 13.6% drop in its shares to $103.50 in pre-market trading [1] Group 2 - uniQure N.V. experienced a significant decline of 65.3% to $23.40 after receiving FDA feedback regarding its investigational gene therapy AMT-130 [3] - ClearPoint Neuro, Inc. shares fell 40.5% to $13.77, while ALPS Group Inc dropped 40.2% to $1.53 following the announcement of a public offering [3] - Biohaven Ltd. shares decreased by 27.4% to $12.48, and Alvotech fell 24.1% to $5.80 after receiving an FDA Complete Response Letter [3] - Replimune Group, Inc. saw a 16.7% dip to $8.10, despite an upgrade from BMO Capital analyst [3] - Praxis Precision Medicines, Inc. declined 9.1% to $180.70, and Vertex, Inc. fell 6.1% to $21.50 after lowering its FY2025 sales guidance [3]